Journal article
Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study
LM FitzGerald, H Naeem, E Makalic, DF Schmidt, JG Dowty, JE Joo, CH Jung, JK Bassett, PA Dugue, J Chung, A Lonie, RL Milne, EM Wong, JL Hopper, DR English, G Severi, L Baglietto, J Pedersen, GG Giles, MC Southey
Prostate | WILEY | Published : 2017
DOI: 10.1002/pros.23289
Abstract
BACKGROUND: Global measures of peripheral blood DNA methylation have been associated with risk of some malignancies, including breast, bladder, and gastric cancer. Here, we examined genome-wide measures of peripheral blood DNA methylation in prostate cancer and its non-aggressive and aggressive disease forms. METHODS: We used a matched, case-control study of 687 incident prostate cancer samples, nested within a larger prospective cohort study. DNA methylation was measured in pre-diagnostic, peripheral blood samples using the Illumina Infinium HM450K BeadChip. Genome-wide measures of DNA methylation were computed as the median M-value of all CpG sites and according to CpG site location and re..
View full abstract